Insider · CIK 0001832343
Rabourn Amy Zaremba
Files at IRD (Ocuphire Pharma, Inc.). First filing Mar 18, 2026, latest Apr 27, 2026.
In brief
Rabourn Amy Zaremba files SEC Form 4 as officer at IRD (Ocuphire Pharma, Inc.). Since Mar 18, 2026, Rabourn Amy Zaremba has reported 0 open-market buys worth $0 and 2 open-market sells worth $23k, the latest filed on Apr 27, 2026.
A track record needs three past buys with six months of prices behind them; Rabourn Amy Zaremba has 0, so none is measured yet.
The newest scored trade: sold $8,540 of IRD on Apr 23, 2026, filed Apr 27, 2026, scored 30 (weak). In the last 12 months: 0 buys worth $0 and 2 sells worth $23k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
IRD: Ocuphire Pharma, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 30Weak | Ocuphire Pharma, Inc. | $8,540 1,641 shares | -1% | +586% from low-9% from high | |
| 30Weak | Ocuphire Pharma, Inc. | $15k 2,816 shares | -1% | +631% from low0% from high |
Transactions
Every row this insider has filed, 8 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Apr 23, 2026 | IRD Ocuphire Pharma, Inc. | SOpen-market sale Common Stock | -1,641 | $5.20 | $8,540 | 188,671 | Apr 27, 2026 |
| Mar 16, 2026 | IRD Ocuphire Pharma, Inc. | SOpen-market sale Common Stock | -2,816 | $5.25 | $15k | 190,312 | Mar 18, 2026 |
| Jan 22, 2026 | IRD Ocuphire Pharma, Inc. | AGrant or award Common Stock | +86,500 | $0.00 | $0 | 193,128 | Jan 26, 2026 |
| Jan 18, 2026 | IRD Ocuphire Pharma, Inc. | FTax withholding Common Stock | -3,390 | $2.10 | $7,119 | 106,628 | Jan 21, 2026 |
| Jan 10, 2026 | IRD Ocuphire Pharma, Inc. | FTax withholding Common Stock | -3,950 | $1.93 | $7,624 | 110,018 | Jan 13, 2026 |
| Jan 18, 2024 | IRD Ocuphire Pharma, Inc. | AGrant or award Common Stock | +40,000 | $0.00 | $0 | 82,658 | Jan 22, 2024 |
| Jan 18, 2024 | IRD Ocuphire Pharma, Inc. | AGrant or award Employee Stock Option (right to buy)derivative | +60,000 | $0.00 | $0 | 60,000 | Jan 22, 2024 |
| Jan 10, 2024 | IRD Ocuphire Pharma, Inc. | FTax withholding Common Stock | -3,950 | $3.27 | $13k | 42,658 | Jan 12, 2024 |
Questions about Rabourn Amy Zaremba
Answered from the filings on this page, as of the latest one.
Is Rabourn Amy Zaremba buying or selling?
In the last 12 months Rabourn Amy Zaremba reported 0 open-market buys worth $0 and 2 open-market sells worth $23k on SEC Form 4; the latest was sold $8,540 of IRD on Apr 23, 2026. Grants, option exercises and tax withholding are not counted.
How did Rabourn Amy Zaremba's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Rabourn Amy Zaremba has 0.
Where does Rabourn Amy Zaremba file Form 4?
Rabourn Amy Zaremba has filed Form 4 at IRD (Ocuphire Pharma, Inc.) as SVP of Finance. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.